Is centralization of ovarian cancer care warranted? A cost-effectiveness analysis by Greving, Jacoba P. et al.
  
 University of Groningen
Is centralization of ovarian cancer care warranted? A cost-effectiveness analysis






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2009
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Greving, J. P., Vernooji, F., Heintz, A. P. M., van der Graaf, Y., & Buskens, E. (2009). Is centralization of
ovarian cancer care warranted? A cost-effectiveness analysis. Gynecologic Oncology, 113(1), 68-74.
https://doi.org/10.1016/j.ygyno.2008.12.008
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Gynecologic Oncology 113 (2009) 68–74
Contents lists available at ScienceDirect
Gynecologic Oncology
j ourna l homepage: www.e lsev ie r.com/ locate /ygynoIs centralization of ovarian cancer care warranted? A cost-effectiveness analysis
Jacoba P. Greving a,⁎,1, Flora Vernooij b,1, A. Peter M. Heintz b, Yolanda van der Graaf a, Erik Buskens c
a Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Internal mailbox Str 6.131, PO Box 85500, 3508 GA Utrecht, The Netherlands
b Department of Gynecologic Surgery and Oncology, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands
c Department of Epidemiology, University Medical Center Groningen, The Netherlands⁎ Corresponding author. Fax: +31 88 755 5480.
E-mail address: J.P.Greving@umcutrecht.nl (J.P. Grev
1 J.P.G. and F.V. contributed equally to this research.
0090-8258/$ – see front matter © 2008 Elsevier Inc. A
doi:10.1016/j.ygyno.2008.12.008a b s t r a c ta r t i c l e i n f oArticle history: Objective. To evaluate th
Received 22 July 2008







Gynecologic oncologiste cost-effectiveness of tertiary referral care for ovarian cancer patients in the
Netherlands.
Methods.We collected clinical and registry data on 1077 newly diagnosed ovarian cancer patients treated
from 1996–2003 in a random sample of Dutch hospitals. Decision modelling was used to compare the cost-
effectiveness of treatment in general hospitals, semi-specialized hospitals, and tertiary care centers. The
actual direct medical costs of ovarian cancer treatment were evaluated. Long-term outcomes in terms of
costs, quality-adjusted life-years (QALYs), and incremental costs per QALY gained were estimated. To assess
uncertainty, multivariable sensitivity analyses and scenario analyses were performed.
Results. Treatment of ovarian cancer patients in semi-specialized hospitals costs on average €882 more
than in general hospitals (95% conﬁdence interval –720 to 2462) and yields 0.12 additional QALYs (95% CI
0.02 to 0.22), resulting in an incremental cost-effectiveness ratio (ICER) of €7135. Patients treated in tertiary
care centers incurred again higher costs (€10,591, 95% CI 8757 to 12,480) and also higher QALYs (0.10, 95% CI
0 to 0.21), resulting in an ICER of €102,642 compared to semi-specialized hospitals. If the optimal debulking
rate in tertiary care centers would increase to 70%, costs could drop below €30,000 per QALY.
Conclusion. Current treatment of ovarian cancer patients in semi-specialized hospital settings is a cost-
effective strategy, while treatment in tertiary care centers becomes only cost-effective when better surgical
results would be achieved.
© 2008 Elsevier Inc. All rights reserved.Introduction
Ovarian cancer is the most lethal gynecologic malignancy. In the
Netherlands, the incidence is about 1100 patients per year and
virtually all 100 hospitals provide primary treatment for these
patients. Several studies in other countries have shown improved
outcome after treatment in specialized hospitals [1–5]. As in many
countries, a heated discussion about centralizing care for ovarian
cancer patients is going on in the Netherlands.
Recently, we have investigated the inﬂuence of hospital specia-
lization on treatment results in the Netherlands [6]. We observed
that patients treated in (semi-)specialized hospital settings signiﬁ-
cantly more often received adequate surgery and survival was better
in these settings [6]. Nevertheless, even in (semi-)specialized
settings surgical outcomes were inferior to results described in
literature [7,8]. Only high-volume specialized gynecologists achieved
outcomes that were comparable to the results in specialized settingsing).
ll rights reserved.in other countries. These ﬁndings support the notion that care in
high-volume, specialized settings is warranted for patients with
ovarian cancer.
Thus far, however, little is known about the balance between costs
and effects of centralized care. Bristow et al. studied the cost-
effectiveness of centralized care for patients with advanced-stage
ovarian cancer and used a decision model to compare two hypothe-
tical extremes: treatment in a non-specialized setting attaining 25%
optimal debulking rates versus treatment in specialized centers with
75% optimal debulking rates and intra-peritoneal chemotherapy [9].
They reported that centralized care for patients with ovarian cancer
would result in cost-effective healthcare [9]. However, in the Nether-
lands, optimal debulking rates in non-specialized settings are slightly
higher. Furthermore, intra-peritoneal chemotherapy is not routine
care, not even in tertiary care centers.
Accordingly, to advance the ongoing discussion and support
considered policy decisions we assessed the clinical beneﬁts and
costs of Dutch ovarian cancer treatment in tertiary care centers,
semi-specialized and general hospital settings using actual patient
data. Furthermore, the incremental cost-effectiveness in scenarios
with the present and with optimal adequate surgery rates was
evaluated.
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Model overview
A decision model was developed to evaluate the cost-effectiveness
of treatment in three different hospital settings [10]. The model was
based on actual patient data regarding 1077 ovarian cancer patients
newly diagnosed between 1996 and 2003 in a random sample of 18
Dutch hospitals. The cohort we used has been described elsewhere [6].
Hospitals were categorized according to specialization. Tertiary care
centers are specialized (usually university) hospitals which employ
gynecologic oncologists. Semi-specialized hospitals are large commu-
nity (and usually teaching) hospitals with a semi-specialized
gynecologist. Semi-specialized gynecologists are not formally trained
in oncology but operate on the majority of the ovarian cancer patients
in the hospitals they work in. Non-specialized hospitals are general
(usually non-teaching) hospitals without (semi-) specialized oncolo-
gic care. Patient and treatment characteristics were collected from
patient records and hospital information systems.
The model includes both a ﬁrst-line treatment phase and a long-
termMarkovmodel phase. The ﬁrst-line treatment phase is structured
as a decision tree; patients could receive optimal, suboptimal or no
surgery, followed by chemotherapy or no adjuvant treatment (Fig. 1).
We distinguished 17 ﬁrst-line treatment options based on prevalence
and prognosis of different disease stages [11]; distribution of patients
across ﬁrst-line treatment options was based on the actual propor-
tions observed in our study cohort (Table 1). The ultimate purpose of
the decision tree was to estimate, for each of the three hospital
settings, the proportion of the patient cohort in each of the three
health states after the ﬁrst-line treatment phase: being progression-
free, having residual or relapsed disease, and death.
The long-term phase is structured as a Markov model with cycles
of three months in duration. Patients may transition between the
three health states during each cycle. Patients who have residual
disease after the ﬁrst-line treatment phase continue in a single
‘residual or relapsed disease’ health state until they die. Patients who
were progression-free after the ﬁrst-line treatment phase can remain
the ‘progression-free’ health state, die, or progress to have relapsed
disease. The Markovmodel estimates long-term survival duration and
costs conditional on the patient's status after the ﬁrst-line treatment
phase. Hence, the differences between hospital settings only relate to
the ﬁrst-line treatment phase.
Measurement of resource use
We used data on health care resource use of all 155 ovarian cancer
patients treated between 2000 and 2003 in six of the participating
hospitals, two hospitals for each type of setting. Information on the
numberof operationsduringﬁrst-line treatmentphase and theduration
of the ﬁrst operation were obtained from patient records. Data on
hospital admission were derived from the National Medical Register
(LMR) maintained by Prismant. The number of outpatient clinic visits
was derived from hospital information systems. Data on the number of
ultrasounds, chest X-rays, CT scans, laboratory tests and pathological
examinations were provided by the hospital's ﬁnancial administration.
The number of gifts and type of chemotherapy administered were
obtained from the patient records from the total study cohort.
Costs
Total surgical costs depended on the operation time and included
personnel costs (gynecologists and surgeons) and operating room
costs. Costs per hour in the operating room were assumed to be
similar for the different hospital settings. The total costs of the ﬁrst-
line treatment phase per hospital setting were determined according
to disease stage, number of operations and administration ofchemotherapy. The costs of follow-up in the progression-free period
and of monitoring and treatment in the period with relapsed disease
were also determined per hospital setting. All cost estimates were
updated to 2006 Euros on the basis of the Dutch inﬂation indices
(http://statline.cbs.nl) and presented in Web Table 1 [12–14].
Health outcomes
The health outcomes of interest were median overall survival and
quality-adjusted life-years. Progression-free survival was deﬁned as
the period of time between the end of the ﬁrst-line treatment phase
and the clinical recurrence of the disease. The probability of disease
recurrence and the risk of dying from ovarian cancer were estimated
by using the life-table method. Because the probability of disease
recurrence decreases with time, we estimated the probability of
disease recurrence for each treatment course through two time
intervals: in the ﬁrst 3 years and at 3–5 years after the ﬁrst-line
treatment phase. We did not distinguish further according to hospital
setting, because we assumed that the progression-free survival would
ﬁrst and foremost depend on disease stage and ﬁrst-line treatment
result rather than on the hospital setting. The short- and long-term
risk of dying from ovarian cancer was estimated in the ﬁrst year and at
1–5 years after recurrent ovarian cancer separately for patients with
early-stage disease and for patients with advanced disease.
Quality-adjusted life-years (QALYs)were calculated bymultiplying
the time a person remained in a certain health state by the utility
associated with that particular health state and subsequent summing
over all health states. Utility weights for the health states of
progression-free (0.85) and residual or relapsed ovarian cancer
(0.65) were derived from data published in the literature [15,16].
Analysis
For the comparison between hospital settings, we used equal
distributions of patients over the various disease stages for all hospital
settings. Expected quality-adjusted life-years and costs for ovarian
cancer treatment according to hospital setting were calculated over
the ten-year time horizon and presented as mean per patient. Costs
and effects were discounted at 4% per year [12]. The analysis of cost-
effectiveness followed standard decision rules using expected costs
and QALYs [17]. If the expected costs of one hospital setting exceeded
the other without the expected gain in health beneﬁts, then this
strategy was dominated and the other was deemed the more cost-
effective. If both the expected costs and health beneﬁts of one setting
exceeded the other, then the incremental cost-effectiveness ratio
(ICER) was calculated as the incremental cost per additional QALY
generated by the more effective setting. Ovarian cancer treatment in a
certain hospital setting was considered cost-effective when the
incremental cost-effectiveness ratio was below €20,000 per QALY
gained. Parameter uncertainty was addressed by means of probabil-
istic sensitivity analysis and was expressed as cost-effectivenesss
acceptability curves (details on thewebsite). In addition, we evaluated
a scenario inwhich the percentage of adequately staged and optimally
debulked patients in tertiary care settings was assumed to be 90% and




The total cohort consisted of 1077 patients. We excluded 198
patients because they could not be classiﬁed according to one of the
pre-deﬁned ﬁrst-line treatment options, leaving 879 patients for the
cost-effectiveness analysis. The majority of the excluded patients had
advanced disease and underwent surgery but declined or otherwise
Fig. 1. General structure of the ﬁrst-line treatment decision tree and long-termMarkov model. The square node represents a decision node and circular nodes are chance nodes. The Markov model is shown by curved branches representing a
single time cycle, with ﬁnal outcomes representing by triangles, deﬁning the state at the start of the subsequent cycle. TheMarkovmodel characterizes a patient's prognosis following the ﬁrst-line treatment phase. Optimal surgery was deﬁned
as adequate staging (i.e. total abdominal hysterectomy, bilateral salpingo-oophorectomy, (partial) omentectomy, at least 1 lymph node removed and at least 1 peritoneal biopsy taken) in patients with stages I-IIa disease and as optimal















Number and percentages of patients per ﬁrst-line treatment option in different hospital settings





1 I–IIa, good⁎ Optimal surgery, no chemotherapy 6 (8%) 8 (18%) 10 (26%)
2 I–IIa, good Non-optimal surgery, no chemotherapy 36 (50%) 11 (25%) 11 (28%)
3 I–IIa, good Non-optimal surgery and chemotherapy 18 (25%) 8 (18%) 6 (15%)
4 I–IIa, good Two operations, no chemotherapy 12 (17%) 17 (39%) 12 (31%)
5 I–IIa, poor⁎⁎ Optimal surgery and chemotherapy 7 (28%) 2 (18%) 6 (46%)
6 I–IIa, poor Non-optimal surgery, no chemotherapy 6 (24%) 3 (27%) 1 (8%)
7 I–IIa, poor Non-optimal surgery and chemotherapy 12 (48%) 3 (27%) 6 (46%)
8 I–IIa, poor Two operations and chemotherapy 0 (0%) 3 (27%) 0 (0%)
9 IIb–IIIa Optimal surgery and chemotherapy 9 (22%) 12 (36%) 8 (26%)
10 IIb–IIIa Non-optimal surgery and chemotherapy 25 (61%) 15 (45%) 15 (58%)
11 IIb–IIIa Two operations and chemotherapy 7 (17%) 5 (15%) 5 (16%)
12 IIb–IIIa No therapy 0 (0%) 1 (3%) 0 (0%)
13 IIIb–IV Optimal debulking and chemotherapy 49 (22%) 51 (30%) 62 (36%)
14 IIIb–IV Non-optimal debulking and chemotherapy 78 (35%) 53 (31%) 37 (21%)
15 IIIb–IV Two debulking operations and chemotherapy 56 (25%) 42 (24%) 56 (32%)
16 IIIb–IV No therapy 29 (13%) 18 (10%) 8 (5%)
17 IIIb–IV Chemotherapy only 13 (6%) 8 (5%) 10 (6%)
⁎ I–IIa good are patients with FIGO I or IIa with a low risk of recurrence (i.e. grade I or II, non-clear cell carcinoma) in whom chemotherapy was not indicated.
⁎⁎ I–IIa poor are patients with FIGO I or IIa with a high risk of recurrence (i.e. grade III or clear cell carcinoma) in whom chemotherapy was indicated [11].
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population was 63 years; women in tertiary care centers tended to be
somewhat younger. There were no signiﬁcant differences between
ovarian cancer patients with or without cost data with respect to
surgical outcome, age and disease stage.
Treatment and effectiveness
Patients with early-stage disease (stages I–IIa) were more often
adequately staged in more specialized hospitals (from general
hospitals to tertiary care centers: 22%, 47% and 46% [P=0.002]).
Patients with stage III disease were slightly more often optimally
debulked in more specialized hospitals (from general hospitals to
tertiary care centers: 37%, 41% and 46% [P=0.3]), but were also
more frequently operated twice in these hospitals. Furthermore,
general hospitals slightly more often refrained from therapy in
patients with advanced disease. The proportion of patients in each
of the 17 ﬁrst-line treatment options differed between the hospital
settings (Table 1). The differences in ﬁrst-line treatment phase
between the hospital settings resulted in better survival in more
specialized hospitals (from general hospitals to tertiary care
centers: predicted median survival was 3.6, 3.8 and 4.1 years).
Costs
A detailed overview of themost relevant cost estimates in the ﬁrst-
line treatment phase is presented in Web Table 2. The major cost
component of ﬁrst-line treatment was chemotherapy costs (from
general hospitals to tertiary care centers: 44%, 41% and 38%).
Operation costs accounted for approximately 9% of ﬁrst-line treatmentTable 2
Mean costs for each 3 months (ie, one Markov cycle) a patient spent in the progression-fre
Mean costs per progression-free interval in the ﬁrst 3 years⁎
General hospitals Semi-specialized hospitals Tertiary car
Inpatient days €3 €16 €23
Outpatient clinic visits €71 €71 €127
Laboratory tests €147 €140 €122
Chemotherapy – – –
Total costs €221 €227 €272
⁎ In the Netherlands, patients are monitored every 3 months in the ﬁrst 3 years of the p
Therefore, the progression-free costs estimates used in the model for the three to ﬁve years
3 years.costs (from general hospitals to tertiary care centers: 11%,10% and 9%).
Total mean costs for each three months spent in the progression-free
period showed no marked differences between the hospital settings
(Table 2). Total mean costs in the residual or relapsed disease period
were highest for patients treated in tertiary care centers. This was
mainly due to the longer length of hospital stay during the periodwith
residual or relapsed disease and the higher unit costs of inpatient
hospital days and outpatient clinic visits in tertiary care centers.
Cost-effectiveness analysis
Expected costs, life-years and QALYs for ovarian cancer treatment
according to hospital setting are presented in Table 3. The expected
costs of ovarian cancer treatment were estimated to be €34,274 in
general hospitals, €35,156 in semi-specialized hospitals and €45,748
in tertiary care centers. Ovarian cancer treatment in semi-specialized
hospitals was estimated to produce 0.12 more QALYs compared to
general hospitals. The incremental cost per QALY was estimated to be
€7135. Ovarian cancer treatment in specialized hospitals was
estimated to produce an additional 0.10 QALYs compared to semi-
specialized hospitals. The incremental cost-effectiveness ratio of
ovarian cancer treatment in tertiary care centers was estimated to
be €102,642. Clearly, ovarian cancer treatment in semi-specialized
hospitals had the lowest cost-effectiveness ratio (Fig. 2A). Results of
the probabilistic sensitivity analysis are depicted in cost-effectiveness
acceptability curves in Fig. 2B. The probability that ovarian cancer
treatment in tertiary care centers is cost-effective is zero at a societal
willingness-to-pay threshold of €20,000 per QALY. If a threshold of
€100,000 per QALY gained would be considered acceptable, the
probability that ovarian cancer treatment in tertiary care centers ise, and residual or relapsed disease health state in different hospitals settings
Mean costs per period of residual or relapsed disease






rogression-free period, every 6 months after 3 years, and annually after 5 years [18].
period were half, and beyond 5 years a quarter of the progression-free costs in the ﬁrst
Table 3












General hospitals 3.53 – 36,111 – –
Semi-specialized hospitals 3.67 0.14 (0.03 to 0.25) 37,054 943 (−707 to 2591) 6630
Tertiary care centers 3.79 0.12 (0.01 to 0.24) 48,403 11,350 (9489 to 13,239) 94,138
Optimal debulking in tertiary care centers 4.02 0.35 (0.23 to 0.47) 45,950 8896 (7172 to 10,695) 25,777
Discounted
General hospitals 3.05 – 34,274 – –
Semi-specialized hospitals 3.18 0.12 (0.02 to 0.22) 35,156 882 (−720 to 2462) 7135
Tertiary care centers 3.28 0.10 (0 to 0.21) 45,748 10591 (8757 to 12,480) 102,642
Optimal debulking in tertiary care centers 3.47 0.29 (0.19 to 0.40) 43,332 8176 (6379 to 10,026) 28,097
⁎ Incremental effectiveness and incremental costs were determined by comparing general hospitals to semi-specialized hospitals and semi-specialized hospitals to tertiary care
centers. The incremental cost-effectiveness ratio was calculated by dividing the incremental costs by the incremental effectiveness. Conﬁdence intervals were derived from the
Monte Carlo simulation (details on website).
Fig. 2. (A) Average costs and effectiveness and incremental cost-effectiveness ratios for the different hospital settings. The incremental cost-effectiveness ratio is given by the slope of
the line joining each successive hospital setting. (B) Cost-effectiveness acceptability curve. The x-axis shows a range of values that society may be willing to pay for an additional
QALY, and the curve's elevation (on the y-axis) denotes the probability that ovarian cancer treatment for a certain hospital setting has a incremental cost-effectiveness ratio that is
more favourable than the corresponding willingness-to-pay.
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considered the preferred healthcare setting for ovarian cancer care,
96% of the estimates (as estimated with bootstrap replicates of the
cohort) would fall below the threshold of €20,000 per QALY.
We conducted a scenario analysis to assess how the incremental
(cost-) effectiveness ratio would change if the surgical results would
be improved in tertiary care centers. If the percentages of adequately
staged and optimally debulked patients in tertiary care settings would
increase to 90% and 70%, respectively, ovarian cancer treatment in
tertiary care centers was estimated to produce 0.29 QALYs more
compared to semi-specialized hospitals. The incremental cost per
QALY of ovarian cancer treatment in tertiary care centers was
estimated to be approximately €28,000 (Table 3).
Discussion
The present study shows that treatment of ovarian cancer patients
according to current practice patterns was most cost-effectively
performed in semi-specialized hospital settings. Treatment in general
hospitals resulted in worse health outcomes at virtually similar costs,
whereas treatment in specialized hospital settings resulted in an
additional survival beneﬁt at much higher costs. However, if the
optimal debulking rate in specialized hospitals would increase to 70%,
ovarian cancer treatment in these hospitals also would become a cost-
effective strategy.
These data signify that there is no place for treatment of ovarian
cancer patients in general hospitals. Furthermore, the present results
seem to argue against systematic referral of ovarian cancer patients to
tertiary care centers. However, this analysis is based on data of patients
treated between 1996 and 2003. In a previous study on this cohort we
indicated that the results of semi-specialized and tertiary care settings
were better than the results in general hospitals, but still lagged behind
theoutcomesdescribed in literature [6–8]. Thepercentage of adequately
staged patients should increase to 90% and the percentage of patients
optimally debulked can be improved to at least 70% according to the
literature [7,8]. Only gynecologic oncologists performing a high volume
of ovarian cancer operations achieved these results. In the present study
we showed that treatmentof patients in such ahigh volume/centralized
setting is a cost-effective strategy.
Our results roughly corroborate those by Bristow et al. [9]. They
reported that centralized care of patients with advanced-stage ovarian
cancer was cost-effective based on hypothetical debulking scenarios.
The model used in the present study was more elaborate; we
additionally took into account patients with early-stage disease,
semi-specialized settings, and costs of follow-up and second-line
treatment. Furthermore, almost all of our cost and effectiveness
estimates were based on actual patient data, whereas Bristow et al.
obtained clinical data and most of the cost estimates from the
literature. The optimal debulking rates in our study population were
higher in the nonspecialized settings and lower in the specialized
settings than the hypothetical debulking rates of Bristow et al.[9].
We feel our study accurately represents current disparities
between hospital settings. The study by Bristow et al. [9] provides
support for the notion that surgical success is an important
determinant of overall survival beneﬁt and subsequently cost-
effectiveness. Indeed, our scenario analyses evaluating a 70% optimal
debulking rate in specialized hospitals indicated that referral to
specialized hospitals would be a cost-effective strategy. The study of
Bristow et al. [9] taken together with our own results provides strong
support for the concept of a concentration of expertise to improve
survival and cost-effectiveness.
Costs in specialized settings could be further reduced by introdu-
cing laparoscopic staging of patients with early-stage disease thereby
reducing the number of inpatient days [19,20]. Furthermore, inpatient
days during the relapsed disease period could be diminished by a
professional, specialized and experienced homecare team taking careof patients in their own house thereby postponing admission until
hospital care is really necessary. Another way to reduce costs could be
to set up specialized clinics focused on tertiary referral care yet
without the ‘academic’ components such as education and research.
Referral of all pelvic masses would create logistical problems. Instead,
pelvic masses with a small chance of being malignant can be
distinguished frommalignant tumors by using the Risk of Malignancy
Index (RMI) [21]. Only patients with a RMI above the cutoff-level
should be referred or operated in the hospital of diagnosis by a
consulting specialized gynecologist.
Our analysis has certain limitations. Firstly, data were retro-
spectively gathered, and we could only count the items that were
registered in patient records, hospital databases and national
registers. However, information on the major cost components
(surgery, inpatient days and chemotherapy) was documented
accurately. Furthermore, we have no reason to believe that there are
substantial differences between hospital settings in the registration of
resource use, and therefore cost differences may assumed to be
accurate. Secondly, we may have underestimated the effect of hospital
specialization on treatment outcomes because patients in general
hospitals were operated on by specialized gynecologists in one-ﬁfth of
the cases. Excluding these patients resulted in a more pronounced
effect of specialization of hospital on survival [6]. We did not exclude
these patients in the present study because we investigated the cost-
effectiveness of the present system and surgery by a consulting
specialized gynecologist is part of this system. Finally, we limited our
analyses of costs to the direct medical costs. However, we do not think
this will lead to a substantial underestimation of the total costs. The
largest indirect costs would be the lost wages. However, the mean age
of our population was 63 years and only a small proportion of the
Dutch women in this age group has a paid job [22].
In conclusion, treatment of ovarian cancer patients in semi-
specialized hospital settings is the most cost-effective strategy at the
moment. If surgical care would be further optimized, referral to high-
volume tertiary care settings also becomes cost-effective. Overall, a
concentration of ovarian cancer expertise and care, and better training
of specialized gynecologists seems warranted, while operating on this
category of patients in general hospitals should no longer be
considered acceptable practice.
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